<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00316784</url>
  </required_header>
  <id_info>
    <org_study_id>CL-033-III-02/E</org_study_id>
    <nct_id>NCT00316784</nct_id>
  </id_info>
  <brief_title>IDEA-033 Three Months Dose Finding in OA Followed by IDEA-033 Three Months Extension in OA</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Evaluation of Dose Related Safety and Efficacy of Epicutaneously Applied IDEA-033 for 3 Months Treatment of OA of the Knee Followed by a Double-Blind, Dose-Controlled Evaluation of Safety and Efficacy of Epicutaneously Applied IDEA-033 for 12 Weeks Treatment of OA of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IDEA AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IDEA AG</source>
  <brief_summary>
    <textblock>
      The study objective is the eluciation of the dose-response function in efficacy (and possibly
      safety) in order to determine an optimal dose with respect to efficacy and safety. The study
      is designed with three dose levels and one placebo control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date>May 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline at week 12 (or end of study measurements) on the Visual Analogue Scale version of the entire WOMAC Pain subscale (primary)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>patient global assessment of response to therapy measured on a 5-point Likert Scale at week 12 or end of study measurements (co-primary)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline at week 12 (or end of study measurements) on the Visual Analogue Scale version of the entire WOMAC function subscale (co-primary)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at week 12 (or end of study measurements) for Physician's Global Assessment of OA and for observed function (TUG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of rescue medication taken per day while in the study</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of withdrawals and time to discontinuation of the study due to lack of efficacy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset (in days) of pain relief and time to onset of new flares during treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on the vitality subscale of the SF-36 health survey and the EURO QoL</measure>
  </secondary_outcome>
  <enrollment>704</enrollment>
  <condition>Osteoarthritis; Knee</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDEA-033 (and rescue medication)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of OA in at least one knee for a minimum of 6 months

          -  aged 18-75 years old

          -  eligible subjects must have used an oral or rectal NSAID on at least three days per
             week during the three months before screening or on at least 25 of the 30 days before
             screening, but be dissatisfied with the current NSAID treatment

          -  at baseline visit WOMAC pain subscale at least 40 mm, and at least 15 mm greater than
             at the screening visit in the index knee

          -  radiographic evidence consistent with OA criteria of grade 2 or 3 according to
             Kellgren &amp; Lawrence in the index knee. Radiographs mus have been taken during the 6
             months before baseline.

          -  American College of Rheumatology (ACR) functional class I, II or III

        Exclusion Criteria:

          -  intraarticular injections or arthroscopy of the index knee within 3 months prior to
             screening, or planned during the study

          -  history, physical examinations or radiographs suggestive of other rhematic diseases

          -  known hypersensitivity or contraindication to ketoprofen; NSAID idiosyncrasy

          -  history of peptic ulcers

          -  severe liver or gastro-intestinal disease within the last 6 months

          -  injections or change in oral treatment regimen of glucosamine, chondroitin sulfate,
             hyaluronic acid, shark cartilage, or vitamin E within 3 months prior to screening

          -  oral or parenteral corticosteroids within 3 months prior to screening

          -  analgesic therapy for chronic or recurrent pain conditions for indications other than
             OA

          -  immunosuppressants within 3 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerold Stucki, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>department of physical medicine and rehabilitation of universtity Munich</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2006</study_first_submitted>
  <study_first_submitted_qc>April 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2006</study_first_posted>
  <last_update_submitted>March 19, 2009</last_update_submitted>
  <last_update_submitted_qc>March 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2009</last_update_posted>
  <keyword>osteoarthritis; knee; IDEA-033</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

